Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by IFP Advisors Inc

IFP Advisors Inc increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,947 shares of the medical equipment provider’s stock after buying an additional 149 shares during the quarter. IFP Advisors Inc’s holdings in Zimmer Biomet were worth $178,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZBH. Truist Financial Corp lifted its holdings in shares of Zimmer Biomet by 34.4% during the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after purchasing an additional 6,867 shares during the last quarter. OneDigital Investment Advisors LLC purchased a new stake in shares of Zimmer Biomet during the first quarter valued at $269,000. State of Alaska Department of Revenue lifted its holdings in shares of Zimmer Biomet by 89.8% during the second quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock valued at $4,036,000 after purchasing an additional 20,945 shares during the last quarter. Thomasville National Bank lifted its holdings in shares of Zimmer Biomet by 3.0% during the second quarter. Thomasville National Bank now owns 105,805 shares of the medical equipment provider’s stock valued at $9,650,000 after purchasing an additional 3,053 shares during the last quarter. Finally, Bridge Creek Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 12.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,133 shares of the medical equipment provider’s stock valued at $2,748,000 after purchasing an additional 3,297 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. BTIG Research upped their target price on Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 13th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. UBS Group upped their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Royal Bank Of Canada set a $111.00 price target on Zimmer Biomet in a research report on Friday, October 10th. Finally, Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Stock Performance

ZBH opened at $102.00 on Friday. The company has a market cap of $20.21 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 2.30 and a beta of 0.67. The stock has a 50-day moving average of $101.74 and a 200-day moving average of $97.88. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.